Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-Intensity Allo-SCT for High-Risk CLL
NCT01027000Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Feb 2010
- Primary completion
- Jan 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by Cancer and Leukemia Group B. Started Feb 2010; status: completed.
02
Drugs
rituximab
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT01027000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01027000.